Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04170348
Other study ID # AAAS0396
Secondary ID R01FD006372
Status Active, not recruiting
Phase Phase 2
First received
Last updated
Start date September 15, 2020
Est. completion date February 28, 2025

Study information

Verified date March 2024
Source Columbia University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study aims to answer the question whether daily oral vitamin D supplementation can reduce the risk of respiratory or lung complications in children and adolescents with sickle cell disease. Respiratory problems are the leading causes of sickness and of death in sickle cell disease. The investigators hypothesize that daily oral vitamin D3, compared to monthly oral vitamin D, will rapidly increase circulating vitamin D3, and reduce the rate of respiratory complications by 50% or more within the first year of supplementation in children and adolescents with sickle cell disease. This study is funded by the FDA Office of Orphan Products Development (OOPD).


Description:

This is a 2-year controlled, double-blind, randomized Phase 2 clinical trial comparing the efficacy in reducing the rate of respiratory events in sickle-cell disease of daily oral vitamin D3 (3,333 IU/d) with monthly bolus oral vitamin D3, (100,000 IU/mo) as a control. The scientific premise of the clinical trial is that circulating concentrations of vitamin D3, the parent compound, are the principal determinant of the anti-infective and immunomodulatory effects of supplementation. Eligible participants will be initially screened to determine their blood vitamin D levels. Those with 25-hydroxyvitamin D levels between 5 and 60 ng/mL will be assigned by chance to one of the two arms for 24 months. Participants will be checked every month and will have periodic blood and urine tests to monitor for any side effects of the study treatments. Children above 5 y/o who can cooperate and understand the procedure will have lung function test at baseline and at 24 months. Showing that a monthly dose of vitamin D reduces lung infections, asthma and the acute chest syndrome could help establish this simple, low-cost treatment as a way to decrease sickness and deaths in children and adolescents with sickle-cell disease.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 69
Est. completion date February 28, 2025
Est. primary completion date June 30, 2024
Accepts healthy volunteers No
Gender All
Age group 3 Years to 20 Years
Eligibility Inclusion Criteria: 1. Diagnosis of sickle cell disease (Hb SS, Hb SC, Hb S-Beta-thalassemia) 2. Age 3-20 years old Exclusion Criteria: 1. Patient unwilling or unable to provide written informed consent (and assent, if applicable) 2. Patient unable or unwilling to comply with requirements of the clinical trial 3. Participation in another clinical trial 4. Current diagnosis of rickets 5. History of hypercalcemia or diagnosis of any medical condition associated with hypercalcemia, including primary hyperparathyroidism, malignancy, sarcoidosis, tuberculosis, granulomatous disease, familial hypocalciuric hypercalcemia 6. Current use of corticosteroids, excluding inhaled steroids 7. Current use of anticonvulsants (phenytoin, phenobarbital, carbamazepine) 8. Therapy with thiazide diuretics or lithium carbonate 9. Known liver or renal disease 10. Patients taking medications for pulmonary complications of sickle cell disease not on a stable dose of medications, as defined by a change in medications or doses within the three months prior to study entry 11. Patients on chronic red blood cell transfusion therapy

Study Design


Intervention

Drug:
Daily oral vitamin D3, 3,333 IU
Oral vitamin D3, 3,333 IU, will be administered daily.
Bolus oral vitamin D3, 100,000 IU
Bolus oral vitamin D3, 100,000 IU, will be administered monthly.
Placebo oral tablet
Participants randomized to receive once monthly oral bolus of vitamin D3, will receive placebo on all other days of the month.

Locations

Country Name City State
United States Columbia University Medical Center New York New York

Sponsors (1)

Lead Sponsor Collaborator
Gary M Brittenham, MD

Country where clinical trial is conducted

United States, 

References & Publications (3)

De A, Anekwe CV, Kattan M, Yao Y, Jin Z, Brittenham GM, Lee MT. Validation of a Questionnaire to Identify Respiratory Tract Infections in Children With Sickle Cell Disease. J Pediatr Hematol Oncol. 2021 Jul 1;43(5):e661-e665. doi: 10.1097/MPH.0000000000002164. — View Citation

Lee MT, Kattan M, Fennoy I, Arpadi SM, Miller RL, Cremers S, McMahon DJ, Nieves JW, Brittenham GM. Randomized phase 2 trial of monthly vitamin D to prevent respiratory complications in children with sickle cell disease. Blood Adv. 2018 May 8;2(9):969-978. doi: 10.1182/bloodadvances.2017013979. — View Citation

Williams KM, Lee MT, Licursi M, Brittenham GM, Fennoy I. Response to Long-term Vitamin D Therapy for Bone Disease in Children With Sickle Cell Disease. J Pediatr Hematol Oncol. 2018 Aug;40(6):458-461. doi: 10.1097/MPH.0000000000001155. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Rate of Respiratory Events Annual rate of respiratory events will be calculated as the sum of respiratory infection, asthma exacerbation, and acute chest syndrome, as ascertained by use of a validated questionnaire. Screening up to month 24
Secondary Change in Forced Vital Capacity (FVC) Change forced vital capacity (FVC; % predicted) from baseline Baseline and month 24
Secondary Change in Forced Expiratory Volume in 1 second (FEV1) Change in Forced Expiratory Volume in 1 second (FEV1; % predicted) from baseline. Baseline and month 24
Secondary Change in Forced Expiratory Volume in 1 second (FEV1)/Forced Vital Capacity ratio Change in Forced Expiratory Volume in 1 second (FEV1; % predicted)/Forced Vital Capacity (FVC) [FEV1/FVC] % predicted from baseline. Baseline and month 24
Secondary Change in Forced Expiratory Flow at 25%-75% vital capacity (FEF25-75) Change in Forced Expiratory Flow at 25%-75% vital capacity (FEF25-75) % predicted from baseline. Baseline and month 24
Secondary Change in ratio of Residual Lung Volume (RV) to Total Lung Capacity (TLC) Change in per cent of the ratio of Residual Lung Volume (RV) to Total Lung Capacity (RV/TLC) from baseline. Baseline and month 24
Secondary Change in Diffusing Capacity of the Lungs for Carbon Monoxide (DLCO) Change in Diffusing Capacity of the Lungs for Carbon Monoxide (DLCO; % predicted) from baseline Baseline and month 24
Secondary Change in Fractional Concentration of Exhaled Nitric Oxide (FENO) Change in Fractional Concentration of Exhaled Nitric Oxide (FENO) in parts per billion (ppb) from baseline Baseline and month 24
Secondary Change in Maximum Inspiratory Pressure (MIP) Change in Maximum Inspiratory Pressure (MIP; cm H2O) from baseline Baseline and month 24
Secondary Change in Maximum Expiratory Pressure (MEP) Change in Maximum Expiratory Pressure (MEP; cm H2O) from baseline Baseline and month 24
Secondary Change in interleukin 2 (IL 2) concentration Change in serum interleukin 2 concentration (IL 2; pg/mL ) from baseline Baseline up to month 24
Secondary Change in interleukin 4 (IL 4) concentration Change in serum interleukin 4 concentration (IL 4; pg/mL ) from baseline Baseline up to month 24
Secondary Change in interleukin 5 (IL 5) concentration Change in serum interleukin 5 concentration (IL 5; pg/mL ) from baseline Baseline up to month 24
Secondary Change in interleukin 13 (IL 13) concentration Change in serum interleukin 13 concentration (IL 13; pg/mL ) from baseline Baseline up to month 24
Secondary Change in interferon gamma (IFN gamma). concentration Change in serum interferon gamma concentration (IFN gamma; pg/mL ) from baseline Baseline up to month 24
Secondary Change in interleukin 10 (IL 10) concentration Change in serum interleukin 10 concentration (Iinterleukin 10; pg/mL ) from baseline Baseline up to month 24
Secondary Change in Transforming Growth Factor beta (TGF beta) Change in serum Transforming Growth Factor beta (TGF beta; pg/mL ) from baseline Baseline up to month 24
Secondary Change in blood hemoglobin concentration (Hb) Change in blood hemoglobin concentration (Hb; g/dL) from baseline Baseline up to month 24
Secondary Change in blood platelet concentration Change in blood platelet concentration (platelets/mL) from baseline Baseline up to month 24
Secondary Change in serum C-reactive protein (CRP) Change in serum C-reactive protein (CRP; mg/L) from baseline Baseline up to month 24
Secondary Change in interleukin 1alpha (IL 1alpha) concentration Change in serum interleukin 1alpha (IL 1alpha; pg/mL) from baseline Baseline up to month 24
Secondary Change in interleukin 1beta (IL 1beta) concentration Change in serum interleukin 1beta (IL 1beta; pg/mL) from baseline Baseline up to month 24
Secondary Change in Tumor Necrosis Factor alpha (TNF alpha) concentration Change in serum Tumor Necrosis Factor alpha (TNF alpha; pg/mL) from baseline Baseline up to month 24
Secondary Change in C-terminal telopeptides of Type I collagen (CTX) Change in serum C-terminal telopeptides of Type I collagen (CTX; ng/mL) from baseline Baseline up to month 24
Secondary Change in intact N-terminal propeptide of type I procollagen (P1NP) Chang in serum intact N-terminal propeptide of type I procollagen (P1NP; µg/L) from baseline.= Baseline up to month 24
See also
  Status Clinical Trial Phase
Terminated NCT04410523 - Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma Phase 2
Completed NCT04624425 - Additional Effects of Segmental Breathing In Asthma N/A
Active, not recruiting NCT03927820 - A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR) N/A
Completed NCT04617015 - Defining and Treating Depression-related Asthma Early Phase 1
Recruiting NCT03694158 - Investigating Dupilumab's Effect in Asthma by Genotype Phase 4
Terminated NCT04946318 - Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma Phase 2
Completed NCT04450108 - Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients N/A
Completed NCT03086460 - A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH) Phase 2
Completed NCT01160224 - Oral GW766944 (Oral CCR3 Antagonist) Phase 2
Completed NCT03186209 - Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE) Phase 3
Completed NCT02502734 - Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma Phase 3
Completed NCT01715844 - L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics Phase 1
Terminated NCT04993443 - First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036 Phase 1
Completed NCT02787863 - Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology Phase 4
Recruiting NCT06033833 - Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study Phase 2
Completed NCT03257995 - Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma. Phase 2
Completed NCT02212483 - Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients N/A
Recruiting NCT04872309 - MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
Withdrawn NCT01468805 - Childhood Asthma Reduction Study N/A
Recruiting NCT05145894 - Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device